Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

Chongqing Huapont to Raise $146 Million in Private Placement

publication date: Mar 26, 2012
 Chongqing Huapont Pharmaceutical announced it will raise 920 million RMB ($146 million) in a private placement. The company said it will spend the proceeds on four projects: 300 million RMB ($47.5 million) on a new R&D center; 280 million RMB ($44.3 million) to increase production capacity; 210 million RMB on a topical formulation facility ($33.3 million), leaving 120 million ($19 million) for general corporate use. The company will issue 25 million shares at 32.99 RMB each. More details....

Stock Symbol:  (SHE: 002004)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China